Chronic Hepatitis B Infection Clinical Trial
Official title:
The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication. In hepatitis B infection, CD4+T Cells are the main effector cells in adaptive immune response. This study was aimed at investigating the changes of CD4+T Cells frequency and function, and the expression of costimulatory molecules during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators want to verify whether Peg IFN - alpha suppressed the virus and the reduction of virus led to the recovery of CD4+T Cells function, or Peg IFN - alpha enhanced CD4+T Cells function which gave rise to the decline of the virus.
Pegylated interferon α-2a(Peg-IFN-α)and Nucleoside analog(ue) drugs can inhibit viral replication , but Peg-IFN-α also play an important role in immune regulation . In hepatitis B infection, CD4+T Cells are the main effector cells in adaptive immune response.Peg-IFN-α recommended as the first-line treatment has a higher chance to achieve HBeAg seroconversion and even HBsAg disappearance than nucleoside analog(ue) drugs, which may be related to the functional activation of CD4+T Cells in the case of hepatitis and the function enhancement of CD4+T Cells during Peg-IFN-α therapy. This study was aimed at investigating the changes of CD4+T Cells frequency and function, and the expression of costimulatory molecules during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators want to explore whether the decline of HBsAg and HBeAg resulted in recovery of CD4+T cells function, or recovery of CD4+T Cells function led to the decrease of HBsAg and HBeAg. Several studies demonstrated that HBsAg and HBeAg could damage CD4+T cells function, and the loss of HBsAg and HBeAg led to recovery of CD4+T cells function. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03329820 -
Quality of Life and Health Utility of Patients With CHB Infections
|
N/A | |
| Recruiting |
NCT04030039 -
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
|
||
| Recruiting |
NCT03210506 -
The Changes of Cytokines During Antiviral Therapy
|
N/A | |
| Recruiting |
NCT03210493 -
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
|
N/A | |
| Recruiting |
NCT03209037 -
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT03210467 -
The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy
|
N/A | |
| Recruiting |
NCT03208998 -
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT04638439 -
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
|
Phase 1 | |
| Recruiting |
NCT03587467 -
Study on Gut Microbiota in Chronic HBV Infected Patients
|
||
| Completed |
NCT05355467 -
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum
|
Phase 4 | |
| Recruiting |
NCT04135235 -
Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
|